NCCN Guidelines® insights: multiple myeloma, version 3.2022: featured updates to the NCCN guidelines
NS Callander, M Baljevic, K Adekola… - Journal of the National …, 2022 - jnccn.org
The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, initial
workup, treatment, follow-up, and supportive care for patients with various plasma cell …
workup, treatment, follow-up, and supportive care for patients with various plasma cell …
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
H Mei, C Li, H Jiang, X Zhao, Z Huang, D Jin… - Journal of Hematology & …, 2021 - Springer
Background BCMA-specific chimeric antigen receptor-T cells (CAR-Ts) have exhibited
remarkable efficacy in refractory or relapsed multiple myeloma (RRMM); however, primary …
remarkable efficacy in refractory or relapsed multiple myeloma (RRMM); however, primary …
[HTML][HTML] Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas
Most relapsed/refractory large B cell lymphoma (r/rLBCL) patients receiving anti-CD19
chimeric antigen receptor (CAR19) T cells relapse. To characterize determinants of …
chimeric antigen receptor (CAR19) T cells relapse. To characterize determinants of …
CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities
LAK Fonkoua, O Sirpilla, R Sakemura… - Molecular Therapy …, 2022 - cell.com
Chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable outcomes in
individuals with hematological malignancies, but its success has been hindered by barriers …
individuals with hematological malignancies, but its success has been hindered by barriers …
[HTML][HTML] Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma
PG Richardson, S Trudel, R Popat… - … England Journal of …, 2023 - Mass Medical Soc
Background Despite recent progress, multiple myeloma remains incurable. Mezigdomide is
a novel cereblon E3 ubiquitin ligase modulator with potent antiproliferative and tumoricidal …
a novel cereblon E3 ubiquitin ligase modulator with potent antiproliferative and tumoricidal …
Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies
X Xiao, S Huang, S Chen, Y Wang, Q Sun… - Journal of Experimental & …, 2021 - Springer
Chimeric antigen receptor (CAR) T-cell therapy has yielded impressive outcomes and
transformed treatment algorithms for hematological malignancies. To date, five CAR T-cell …
transformed treatment algorithms for hematological malignancies. To date, five CAR T-cell …
Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
Hematological toxicity is the most common adverse event after chimeric antigen receptor
(CAR) T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for …
(CAR) T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for …
Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)
WH Zhao, BY Wang, LJ Chen, WJ Fu, J Xu… - Journal of Hematology & …, 2022 - Springer
Abstract Background LCAR-B38M is a chimeric antigen receptor T cell product with two
binding domains targeting B cell maturation antigen. Our previous reports showed a …
binding domains targeting B cell maturation antigen. Our previous reports showed a …
The future of engineered immune cell therapies
Immune cells are being engineered to recognize and respond to disease states, acting as a
“living drug” when transferred into patients. Therapies based on engineered immune cells …
“living drug” when transferred into patients. Therapies based on engineered immune cells …
How I treat cytopenias after CAR T-cell therapy
Increasing use of chimeric antigen receptor T-cell therapy (CAR-T) has unveiled diverse
toxicities warranting specific recognition and management. Cytopenias occurring after CAR …
toxicities warranting specific recognition and management. Cytopenias occurring after CAR …